布地奈德在原发性IgA肾病中的靶向释放 - Suppr | 超能文献

Targeted release of budesonide in primary IgA nephropathy.

作者信息

Hu Yitong, Zhang Yuemiao

机构信息

Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China; Institute of Nephrology, Peking University, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China; Peking University Health Science Center, Beijing, China.

Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China; Institute of Nephrology, Peking University, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.

出版信息

Lancet. 2024 Jun 29;403(10446):2785. doi: 10.1016/S0140-6736(24)00794-3.

DOI:10.1016/S0140-6736(24)00794-3

Abstract

摘要

相似文献

1

Targeted release of budesonide in primary IgA nephropathy.

Lancet. 2024 Jun 29;403(10446):2785. doi: 10.1016/S0140-6736(24)00794-3.

2

Targeted release of budesonide in primary IgA nephropathy.

Lancet. 2024 Jun 29;403(10446):2785-2786. doi: 10.1016/S0140-6736(24)00795-5.

3

Targeted release of budesonide in primary IgA nephropathy - Authors' reply.

Lancet. 2024 Jun 29;403(10446):2786. doi: 10.1016/S0140-6736(24)00796-7.

4

Childhood IgA Nephropathy Successfully Treated with Targeted-Release Budesonide: A Case Report.

J Paediatr Child Health. 2018 Dec;54(12):1403. doi: 10.1111/jpc.14259.

5

Delayed-Release Budesonide in a Patient With Progressive IgA Nephropathy and Stage 4 Chronic Kidney Disease: A Case Report.

J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241260964. doi: 10.1177/23247096241260964.

6

Mucosal corticosteroid therapy of IgA nephropathy.

Kidney Int. 2017 Aug;92(2):278-280. doi: 10.1016/j.kint.2017.05.021.

7

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

8

Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide.

Saudi J Kidney Dis Transpl. 2020 Mar-Apr;31(2):521-523. doi: 10.4103/1319-2442.284029.

9

Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.

Front Immunol. 2023 Jan 4;13:926517. doi: 10.3389/fimmu.2022.926517. eCollection 2022.

10

Should we really STOP treating patients with IgA nephropathy with steroids?

Physiol Int. 2018 Jun 1;105(2):101-109. doi: 10.1556/2060.105.2018.2.10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。